盘前涨超81% 癌症制药商Immunogen(IMGN.US)获艾伯维(ABBV.US)约100亿美元收购

智通财经网2023-11-30

智通财经APP获悉，艾伯维(ABBV.US)周四宣布，已同意以约100亿美元的现金收购新型抗癌疗法抗体偶联药物(ADC)开发商Immunogen(IMGN.US)。消息公布后，截至发稿，Immunogen股价飙升逾81%。根据条款，艾伯维将为每股ImmunoGen股票支付31.26美元现金，较前一日收盘价溢价94.6%。艾伯维表示，这项交易预计将于2024年中期完成。此次收购Immunogen将...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2387444037?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20231130/20231130214149_59403.png?x-oss-process=image/format,jpg/quality,Q_80","is_english":false,"pubTime":"2023-11-30 21:39","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2387444037","market":"sg","top_or_hot":-1,"title":"盘前涨超81% 癌症制药商Immunogen(IMGN.US)获艾伯维(ABBV.US)约100亿美元收购","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，艾伯维(ABBV.US)周四宣布，已同意以约100亿美元的现金收购新型抗癌疗法抗体偶联药物(ADC)开发商Immunogen(IMGN.US)。消息公布后，截至发稿，Immunogen股价飙升逾81%。根据条款，艾伯维将为每股ImmunoGen股票支付31.26美元现金，较前一日收盘价溢价94.6%。艾伯维表示，这项交易预计将于2024年中期完成。此次收购Immunogen将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1031870.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>盘前涨超81% 癌症制药商Immunogen(IMGN.US)获艾伯维(ABBV.US)约100亿美元收购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n盘前涨超81% 癌症制药商Immunogen(IMGN.US)获艾伯维(ABBV.US)约100亿美元收购\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-30 21:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1031870.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，艾伯维(ABBV.US)周四宣布，已同意以约100亿美元的现金收购新型抗癌疗法抗体偶联药物(ADC)开发商Immunogen(IMGN.US)。消息公布后，截至发稿，Immunogen股价飙升逾81%。根据条款，艾伯维将为每股ImmunoGen股票支付31.26美元现金，较前一日收盘价溢价94.6%。艾伯维表示，这项交易预计将于2024年中期完成。此次收购Immunogen将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1031870.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1031870.html","article_id":"2387444037","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20231130/20231130214149_59403.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2387444037","pubTimestamp":1701351597,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"艾伯维周四宣布，已同意以约100亿美元的现金收购新型抗癌疗法抗体偶联药物开发商Immunogen。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","IMGN":"ImmunoGen","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4559":"巴菲特持仓","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK1191":"制药","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BK4581":"高盛持仓","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","ABBV":"艾伯维公司","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK1574":"生物医药B类股","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4566":"资本集团","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","01477":"欧康维视生物-B","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H"},"translate_title":"Cancer drugmaker Immunogen (IMGN.US), which rose more than 81% before the market, was acquired by ABBV.US for about 10 billion US dollars","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"01477":1,"IMGN":1},"content_text":"智通财经APP获悉，艾伯维(ABBV.US)周四宣布，已同意以约100亿美元的现金收购新型抗癌疗法抗体偶联药物(ADC)开发商Immunogen(IMGN.US)。消息公布后，截至发稿，Immunogen股价飙升逾81%。根据条款，艾伯维将为每股ImmunoGen股票支付31.26美元现金，较前一日收盘价溢价94.6%。艾伯维表示，这项交易预计将于2024年中期完成。此次收购Immunogen将包括卵巢癌症疗法Elahere，艾伯维预计，从2027年初开始，这一收购将提高其摊薄后每股收益。首席执行官Richard  Gonzalez表示：“收购ImmunoGen表明了我们致力于实现长期增长战略的承诺，并使艾伯维能够在实体肿瘤和血液系统恶性肿瘤领域进一步实现产品管线的多元化。”该协议也标志着生物技术公司在ADC领域的最新进展。据了解，ADC药物是一种新型的靶向治疗药物，被广泛用于癌症治疗。辉瑞(PFE.US)正在等待以430亿美元收购ADC开发商Seagen(SGEN.US)的交易完成。10月，默沙东(MRK.US)同意向日本制药公司Daiichi  Sankyo(DSKYF.US)支付高达220亿美元，共同开发和商业化三种针对实体肿瘤的ADC。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2387444037"}